Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.

<h4>Background</h4>The Emergency Use Authorization (EUA) of remdesivir for coronavirus disease 2019 raised questions on transparency of applied strategy, and how to equitably allocate and prioritize eligible patients given limited supply of the medication. The absence of federal oversigh...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zippora Kiptanui, Sanchari Ghosh, Sabeen Ali, Karishma Desai, Ilene Harris
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a8266d8db6ee432ea9b7af4b6e7d49bd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a8266d8db6ee432ea9b7af4b6e7d49bd
record_format	dspace
spelling	oai:doaj.org-article:a8266d8db6ee432ea9b7af4b6e7d49bd2021-12-02T20:07:51ZTransparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.1932-620310.1371/journal.pone.0257648https://doaj.org/article/a8266d8db6ee432ea9b7af4b6e7d49bd2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0257648https://doaj.org/toc/1932-6203<h4>Background</h4>The Emergency Use Authorization (EUA) of remdesivir for coronavirus disease 2019 raised questions on transparency of applied strategy, and how to equitably allocate and prioritize eligible patients given limited supply of the medication. The absence of federal oversight highlighted the critical role by states in health policymaking during a pandemic.<h4>Objective</h4>To identify public state-based protocols for remdesivir allocation and clinical guidance for prioritizing remdesivir use and assess approaches and inclusion of language promoting equitable access or mitigating health disparities.<h4>Methods</h4>We identified remdesivir allocation strategies and clinical use guidelines for all 50 states in the U.S. and the District of Columbia accessible on state health department websites or via internet searches. Public protocols dated between May 1, 2020 and September 30, 2020 were included in the study. We reviewed strategies for allocation and clinical use, including whether protocols contained explicit language on equitable access to remdesivir or mitigating health disparities.<h4>Results</h4>A total of 38 states had a remdesivir allocation strategy, with 33 states (87%) making these public. States used diverse allocation strategies, and only 10 (30%) of the 33 states included language on equitable allocation. A total of 30 states had remdesivir clinical use guidelines, where all were publicly accessible. All guidelines referenced recommendations by federal agencies but varied in their presentation format. Of the 30 states, 12 (40%) had guidelines that included language on equitable use. Neither an allocation strategy or clinical use guideline were identified (public or non-public) for 10 states and the District of Columbia during the study period.<h4>Conclusions</h4>The experience with the remdesivir EUA presents an opportunity for federal and state governments to develop transparent protocols promoting fair and equal access to treatments for future pandemics.Zippora KiptanuiSanchari GhoshSabeen AliKarishma DesaiIlene HarrisPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0257648 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Zippora Kiptanui Sanchari Ghosh Sabeen Ali Karishma Desai Ilene Harris Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.
description	<h4>Background</h4>The Emergency Use Authorization (EUA) of remdesivir for coronavirus disease 2019 raised questions on transparency of applied strategy, and how to equitably allocate and prioritize eligible patients given limited supply of the medication. The absence of federal oversight highlighted the critical role by states in health policymaking during a pandemic.<h4>Objective</h4>To identify public state-based protocols for remdesivir allocation and clinical guidance for prioritizing remdesivir use and assess approaches and inclusion of language promoting equitable access or mitigating health disparities.<h4>Methods</h4>We identified remdesivir allocation strategies and clinical use guidelines for all 50 states in the U.S. and the District of Columbia accessible on state health department websites or via internet searches. Public protocols dated between May 1, 2020 and September 30, 2020 were included in the study. We reviewed strategies for allocation and clinical use, including whether protocols contained explicit language on equitable access to remdesivir or mitigating health disparities.<h4>Results</h4>A total of 38 states had a remdesivir allocation strategy, with 33 states (87%) making these public. States used diverse allocation strategies, and only 10 (30%) of the 33 states included language on equitable allocation. A total of 30 states had remdesivir clinical use guidelines, where all were publicly accessible. All guidelines referenced recommendations by federal agencies but varied in their presentation format. Of the 30 states, 12 (40%) had guidelines that included language on equitable use. Neither an allocation strategy or clinical use guideline were identified (public or non-public) for 10 states and the District of Columbia during the study period.<h4>Conclusions</h4>The experience with the remdesivir EUA presents an opportunity for federal and state governments to develop transparent protocols promoting fair and equal access to treatments for future pandemics.
format	article
author	Zippora Kiptanui Sanchari Ghosh Sabeen Ali Karishma Desai Ilene Harris
author_facet	Zippora Kiptanui Sanchari Ghosh Sabeen Ali Karishma Desai Ilene Harris
author_sort	Zippora Kiptanui
title	Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.
title_short	Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.
title_full	Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.
title_fullStr	Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.
title_full_unstemmed	Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.
title_sort	transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/a8266d8db6ee432ea9b7af4b6e7d49bd
work_keys_str_mv	AT zipporakiptanui transparencyhealthequityandstrategiesinstatebasedprotocolsforremdesivirallocationanduse AT sancharighosh transparencyhealthequityandstrategiesinstatebasedprotocolsforremdesivirallocationanduse AT sabeenali transparencyhealthequityandstrategiesinstatebasedprotocolsforremdesivirallocationanduse AT karishmadesai transparencyhealthequityandstrategiesinstatebasedprotocolsforremdesivirallocationanduse AT ileneharris transparencyhealthequityandstrategiesinstatebasedprotocolsforremdesivirallocationanduse
_version_	1718375260522283008

Transparency, health equity, and strategies in state-based protocols for remdesivir allocation and use.

Ejemplares similares